ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Seeking Alpha
SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products. While neffy's expansion into chronic urticaria is a potential catalyst, current valuation (~10x sales) appears stretched without clear growth visibility. Looking for higher risk/reward options trading ideas? I offer this and much more at my exclusive investing ideas service, Haggerston BioHealth. Learn More » J Studios/DigitalVision via Getty Images Investment Overview I first covered ARS Pharmaceuticals, Inc. ( SPRY ) for Seeking Alpha in September 2024 , issuing stock with a Buy rating, shortly after its product candidate neffy, a nasal spray, was More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and health
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.MarketBeat
- ARS Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 3/9/26 - In-Line
SPRY
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 10-K
- 3/9/26 - Form 8-K
- SPRY's page on the SEC website